Key Drivers
- Strong liquidity
- Thin net margins
- Elevated valuation
AIAI Summary
Artivion has shifted from an R&D‑led story to an execution- and regulatory-driven investment where near‑term upside hinges on converting AMDS stocking into durable implant sell‑through, On‑X share gains, and the timing/outcome of key PMA/NEXUS events; failure on these cadence milestones or implant adoption would rapidly compress the richly priced valuation. Monitor AMDS implant sell‑through rates, PMA readout timelines (mid‑2026 AMDS PMA), margin/FCF conversion, and the $35/$38.5 technical levels as clear action points for downside risk or returning investor confidence.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Thin net margins
- •Elevated valuation
AORT has strong liquidity and gross profitability but delivers only minimal net income and free cash flow while trading at highly elevated multiples that imply significant improvement not yet realized.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Lower highs/lows
- •Defined support
AORT has been in a short-term downtrend over the last month (down ~7–8% to $35.31) trading ~4.7% below its 21-day SMA (~$37.07) with resistance clustered at $38.50–$38.66 and support around $35.31–$35.35 (break below ~$35.00 would raise downside risk).
High-low range near 9–10% ($38.66 to $35.31) indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Virtual engagement
- •Aortic specialization
- •Investor visibility
Artivion will host a virtual fireside chat at the Oppenheimer Healthcare MedTech & Services Conference, underscoring targeted investor outreach and reinforcing its aortic surgery specialization.
The appearance should modestly increase investor awareness but offers no new operational or financial information likely to materially alter the stock's outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings